Canada

Appili Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

First clinical study to examine the use of favipiravir for COVID-19 outbreak control; National Institute on Ageing estimates over 80 per cent of COVID-19 deaths in Canada are occurring at long-term care facilities.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Arch Biopartners Expands Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

Lead Product(s): LSALT peptide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

The expansion of primary endpoint of the Phase II human trial for LSALT reflects recent global data from COVID-19 patients that shows the SARS-CoV-2 virus results in damage to organs besides the lungs and Metablok’s potential to prevent inflammation injury in multiple organs.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

Lead Product(s): LSALT peptide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

Details:

The Phase II trial will be a multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Algernon Re-purposes Ifenprodil Drug Against COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

Phase 2 trial is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Algernon Pharma receives South Korean regulatory approval to begin phase 2 COVID-19 study of Ifenprodil

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2020

Details:

Algernon has received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval for a Phase 2 COVID-19 clinical study of NP-120 (Ifenprodil).

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2020

Details:

The protocol for a planned physician initiated phase 2 clinical study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea has been finalized.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Appili Therapeutics

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

Arch Biopartners

Arch Biopartners Expands Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

Arch Biopartners

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

Algernon Pharmaceuticals

Algernon Re-purposes Ifenprodil Drug Against COVID-19

Algernon Pharmaceuticals

Algernon Pharma receives South Korean regulatory approval to begin phase 2 COVID-19 study of Ifenprodil

Algernon Pharmaceuticals

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19